-
公开(公告)号：US20130065786A1
公开(公告)日：2013-03-14
申请号：US13638360
申请日：2011-03-29
申请人： Mareike Dartmann , Inke Sabine Feder , Mathias Gehrmann , Guido Hennig , Karsten Weber , Christian Von Törne , Ralf Kronenwett , Christoph Petry
发明人： Mareike Dartmann , Inke Sabine Feder , Mathias Gehrmann , Guido Hennig , Karsten Weber , Christian Von Törne , Ralf Kronenwett , Christoph Petry
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.
摘要翻译： 本发明涉及用于乳腺癌疾病预后的方法，试剂盒和系统，所述方法包括：（a）在所述患者的肿瘤样品中测定以下9个基因中至少2个的RNA表达水平： UBE2C，BIRC5，RACGAP1，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP（b）在数学上组合所述组的基因的表达水平值，其在肿瘤样品中测定以产生组合评分，其中所述组合 评分表示所述患者的预后; 以及用于执行所述方法的套件和系统。
-
2.发明申请ALGORITHMS FOR OUTCOME PREDICTION IN PATIENTS WITH NODE-POSITIVE CHEMOTHERAPY-TREATED BREAST CANCER 审中-公开患有结直肠癌治疗乳腺癌的患者的预后预测方法公开(公告)号：US20110166838A1
公开(公告)日：2011-07-07
申请号：US12999522
申请日：2009-06-16
IPC分类号： G06F7/60
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G16B20/00 , G16B25/00 , G16B40/00
摘要： The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.
摘要翻译： 本发明涉及用于预测患有癌症的患者的癌症结果的方法，所述患者先前被诊断为淋巴结阳性并用细胞毒性化疗治疗，所述方法包括在来自所述患者的生物样品中确定多个表达水平 选自ACTG1，CA2，CALM2，CCND1，CHPT1，CLEC2B，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3， KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF; ABCB1，ABCG2，ADAM15，AKR1C1，AKR1C3，AKT1，BANF1，BCL2，BIRC5，BRMS1，CASP10，CCNE2，CENPJ，CHPT1，EGFR，CTTN，ERBB3，ERBB4，FBLN1，FIP1L1，FLT1，FLT4，FNTA，GATA3，GSTP1， Herbatin，IGF1R，IGHM，KDR，KIT，CKRT5，SLC39A6，MAPK3，MAPT，MKI67，MMP7，MTA1，FRAP1，MUC1，MYC，NCOA3，NFIB，OLFM1，TP53，PCNA，PI3K，PPERLD1，RAB31，RAD54B，RAF1， SCUBE2，STAU，TINF2，TMSL8，VGLL1，TRA @，TUBA1，TUBB，TUBB2A。
-
3.发明申请公开(公告)号：US20140228241A1
公开(公告)日：2014-08-14
申请号：US14235168
申请日：2012-07-30
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.
摘要翻译： 一种在患有或有发生复发性肿瘤疾病，特别是乳腺癌风险的患者中预测化疗（包括新辅助化疗）的反应和/或益处的方法，所述方法包括以下步骤：（a）在 来自所述患者的肿瘤样品包括以下8个基因：UBE2C，RACGAP1，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP的RNA表达水平，其指示对肿瘤的化学疗法的反应，或（b）在肿瘤中测定 来自所述患者的样品来自以下8个基因的RNA表达水平：UBE2C，BIRC5，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP; 指示对肿瘤的化学疗法的反应（c）在数学上组合所述组的基因的表达水平值，所述基因在肿瘤样品中测定以产生组合评分，其中所述组合评分预测所述应答和/或益处 的化疗。
-
公开(公告)号：US20110172928A1
公开(公告)日：2011-07-14
申请号：US12999406
申请日：2009-06-16
IPC分类号： G06F19/00
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , G16B20/00 , G16B25/00 , G16B40/00
摘要： The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.
摘要翻译： 本发明涉及用于预测肿瘤性疾病或癌症的结果的方法。 更具体地，本发明涉及通过在来自所述患者的生物样品中测定多种选自ACTG1，CA12，CALM2，CCND1，CHPT1，CLEC2B的多种基因的表达水平来预测乳腺癌的方法 ，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3，KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5 ，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF。
-
公开(公告)号：US07668661B2
公开(公告)日：2010-02-23
申请号：US10868437
申请日：2004-06-15
申请人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan , Robert P. Thiel , Christoph Petry , William Rosenberg
发明人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan , Robert P. Thiel , Christoph Petry , William Rosenberg
IPC分类号： G06F7/00
CPC分类号： C12Q1/6883 , G01N33/6893 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , Y02A90/26
摘要： The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient.The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.
摘要翻译： 本发明提供了诊断方法，试剂盒和系统以及相关的计算机可读介质，其使用多个血液标记值，包括血清和血浆标记值，以帮助诊断患者的肝脏疾病的状态或进展。 本发明还提供了使用血液标记值（包括血清和血浆标记值）的方法和系统以及相关的计算机可读介质：（1）筛选可用于治疗肝脏疾病的活性成分; （2）协助选择易患或患有肝病的患者的治疗方案; （3）协助设计有用的一个或多个病人监测肝脏病状况或进展情况的临床方案。
-
公开(公告)号：US20070172907A1
公开(公告)日：2007-07-26
申请号：US10868437
申请日：2004-06-15
申请人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael Arthur , Alastair Burt , Massimo Pinzani , Detlef Schuppan , Robert Thiel , Christoph Petry , William Rosenberg
发明人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael Arthur , Alastair Burt , Massimo Pinzani , Detlef Schuppan , Robert Thiel , Christoph Petry , William Rosenberg
CPC分类号： C12Q1/6883 , G01N33/6893 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , Y02A90/26
摘要： The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.
摘要翻译： 本发明提供了诊断方法，试剂盒和系统以及相关的计算机可读介质，其使用多个血液标记值，包括血清和血浆标记值，以帮助诊断患者的肝脏疾病的状态或进展。 本发明还提供了使用血液标记值（包括血清和血浆标记值）的方法和系统以及相关的计算机可读介质：（1）筛选可用于治疗肝脏疾病的活性成分; （2）协助选择易患或患有肝病的患者的治疗方案; （3）协助设计有用的一个或多个病人监测肝脏病状况或进展情况的临床方案。
-
公开(公告)号：US20090311700A1
公开(公告)日：2009-12-17
申请号：US12441748
申请日：2007-09-25
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118
摘要： The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer.
摘要翻译： 本发明涉及未经治疗的乳腺癌患者乳腺癌预后的方法，试剂盒和系统。 更具体地说，本发明是基于乳腺癌患者肿瘤样本中标记基因表达水平的测定，涉及乳腺癌的预后。 公开了标记基因，其允许在具有淋巴结阴性，快速增殖的乳腺癌的患者中对乳腺癌的准确预后。
-
公开(公告)号：US20090239223A1
公开(公告)日：2009-09-24
申请号：US12307590
申请日：2007-07-06
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.
摘要翻译： 本发明涉及用于预测癌症患者化学疗法可能结果的方法和试剂盒。 更具体地，本发明涉及基于对一小组标记基因的表达水平的测量来预测肿瘤对化学疗法的反应。 该组标记基因可用于鉴定对基于紫杉烷的化学疗法有效的乳腺癌亚型，例如， 紫杉烷 - 蒽环类 - 环磷酰胺（如泰索帝（多西紫杉醇） - 阿霉素（多柔比星） - 环磷酰胺，即（TAC））化疗。
-
公开(公告)号：US20090222387A1
公开(公告)日：2009-09-03
申请号：US11922276
申请日：2006-06-14
IPC分类号： G06F15/18
摘要： The present invention relates to methods and compositions for the diagnosis, prognosis, and prediction of breast cancer. More specifically, the invention relates to classification of breast cancer tissue samples based on measuring the expression of a set of marker genes. The set is useful for the identification of clinically important breast cancer subtypes. Methods are disclosed for prediction, diagnosis and prognosis of breast cancer.
摘要翻译： 本发明涉及用于乳腺癌诊断，预后和预测的方法和组合物。 更具体地，本发明涉及基于测量一组标记基因的表达的乳腺癌组织样品的分类。 该组对于鉴定临床重要的乳腺癌亚型是有用的。 公开了乳腺癌预测，诊断和预后的方法。
-
公开(公告)号：US07141380B2
公开(公告)日：2006-11-28
申请号：US10258689
申请日：2001-04-26
申请人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Mathias Gehrmann , Guido Hennig , Sylvia Unger , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan
发明人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Mathias Gehrmann , Guido Hennig , Sylvia Unger , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2333/47 , G01N2333/78 , G01N2333/8146 , G01N2333/96486 , G01N2800/085
摘要： The present invention concerns a method for diagnosing liver fibrosis wherein two or more diagnostic markers are measured and the measurements are correlated by a mathematic algorithm characterized in that the diagnostic markers are selected from the group N-terminal procollagen III propeptide (PIIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex. The algorithm can be used to predict the histological score of a liver biopsy.
摘要翻译： 本发明涉及一种用于诊断肝纤维化的方法，其中测量两个或更多个诊断标记物，并且通过数学算法将测量值相关联，其特征在于诊断标记物选自N-末端原胶原III前肽（PIIINP），胶原蛋白IV ，胶原VI，腱生蛋白，层粘连蛋白，透明质酸，MMP-2，TIMP-1和MMP-9 / TIMP-1复合物。 该算法可用于预测肝活组织检查的组织学分数。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.035 秒)